Compare Smith & Nephew plc (SNN) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs VICI Properties Inc — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while VICI Properties Inc trades at $22.89 (market cap $25.09B). The key difference: VICI Properties Inc is far larger — about 2.3× Smith & Nephew plc's market cap, and VICI Properties Inc pays the higher dividend (8.07%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and VICI Properties Inc for 42 Days on average.
| SNN | VICI | |
|---|---|---|
Market Cap | $11.10B | $25.09B |
Volume | 1,051,703 | 17,066,337 |
Sector | Health | Real Estate |
52-Week High | $37.17 | $31.42 |
52-Week Low | $26.42 | $22.53 |
Typical Hold Time | 120 Days | 42 Days |
Enterprise Value | $14.13B | $42.65B |
Dividend Yield | 2.95% | 8.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical signal driven by moving averages. The stock shows attractive valuation metrics, including a P/E of 8.78 and P/B of 0.85, alongside strong profitability with a net income margin of 67.5%. Recent earnings have been mixed, with a beat in Q1 2026 but misses in Q4 2025 and Q2 2026. The company maintains robust cash flow from operations of $2.51 billion in 2025 and recently announced a dividend of $0.46 per share payable in October 2026.
The outlook for VICI is supported by solid fundamentals and a 75% analyst buy rating, with a consensus price target of $28.90 implying significant upside. However, risks include tenant concentration concerns, as highlighted in recent news, and the bearish technical trend. The stock offers value and income potential but faces headwinds from market sentiment and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
